Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis

RMD Open

Volumn 2, Issue 1, 2016, Pages

  Meijs, Jessica ^a   Schouffoer, Anne A ^a,b   Marsan, Nina Ajmone ^a   Kroft, Lucia J M ^a   Stijnen, Theo ^a   Ninaber, Maarten K ^a   Huizinga, Tom W J ^a   Vliet Vlieland, Theodora P M ^a   De Vries Bouwstra, Jeska K ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HAGA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84988416827     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2015-000159     Document Type: Article

References (39)

1. Elhai M, Meune C, Avouac J, et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2012;51:1017-26.
2. Steen VD, Medsger TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
3. Nihtyanova SI, Tang EC, Coghlan JG, et al. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 2010;103:109-15.
4. Nihtyanova SI, Schreiber BE, Ong VH, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheum 2014;66:1625-35.
5. Coghlan JG, Denton CP, Grunig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014;73:1340-9.
6. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008;177:1248-54.
7. Valentini G. The assessment of the patient with systemic sclerosis. Autoimmun Rev 2003;2:370-6.
8. Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2007;66:754-63.
9. Khanna D, Denton CP. Evidence-based management of rapidly progressing systemic sclerosis. Best Pract Res Clin Rheumatol 2010;24:387-400.
10. Mierau R, Moinzadeh P, Riemekasten G, et al. Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther 2011;13:R172.
11. Moinzadeh P, Nihtyanova SI, Howell K, et al. Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma. Clin Rev Allergy Immunol 2012;43:249-55.
12. Willems LM, Vriezekolk JE, Schouffoer AA, et al. Effectiveness of nonpharmacologic interventions in systemic sclerosis: a systematic review. Arthritis Care Res (Hoboken) 2015;67:1426-39.
13. Avouac J, Kowal-Bielecka O, Landewe R, et al. European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research. Ann Rheum Dis 2009;68:629-34.
14. Schouffoer AA, Zirkzee EJ, Henquet SM, et al. Needs and preferences regarding health care delivery as perceived by patients with systemic sclerosis. Clin Rheumatol 2011;30:815-24.
15. Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620-8.
16. [No authors listed]. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
17. Leroy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
18. Medsger TA Jr. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am 2003;29:255-73, vi.
19. Cutolo M, Sulli A, Pizzorni C, et al. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 2000;27:155-60.
20. Clements PJ, Wong WK, Hurwitz EL, et al. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis Rheum 2001;44:653-61.
21. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-17.
22. Ware JJ, Snow K, Kosinki M. SF-36 Health survey manual and interpretation guide. Boston, MA: The Health Institute, New England Medical Center, 1994.
23. Newnham EA, Harwood KE, Page AC. Evaluating the clinical significance of responses by psychiatric inpatients to the mental health subscales of the SF-36. J Affect Disord 2007;98:91-7.
24. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304.
25. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010;23:685-713.
26. Vacca A, Meune C, Gordon J, et al. Cardiac arrhythmias and conduction defects in systemic sclerosis. Rheumatology 2014;53:1172-7.
27. van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014;311:2490-8.
28. Meijs J, Zirkzee EJ, Schouffoer AA, et al. Health-care utilization in Dutch systemic sclerosis patients. Clin Rheumatol 2014;33:825-32.
29. Zhang SZ, Xu D, Li MT, et al. Telangiectasia as a potential clinical marker of microvascular lesions in systemic sclerosis patients from EUSTAR data. Clin Exp Rheum 2015;33(4 Suppl 91):S106-10.
30. Khanna D, Kowal-Bielecka O, Khanna PP, et al. Quality indicator set for systemic sclerosis. Clin Exp Rheumatol 2011;29(2 Suppl 65): S33-9.
31. Muangchan C, Baron M, Pope J. The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review. J Rheumatol 2013;40:1545-56.
32. Schade L, Paiva ES, Muller CS. Skeletal and cardiac muscles involvement in systemic sclerosis. Rev Bras Reumatol 2011;51:309-10, 313.
33. Maurer B, Graf N, Michel BA, et al. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis 2015;74:1124-31.
34. Jung M, Bonner A, Hudson M, et al. Myopathy is a poor prognostic feature in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG) cohort. Scand J Rheum 2014;43:217-20.
35. Pieroni M, De Santis M, Zizzo G, et al. Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression. Semin Arthritis Rheum 2014; 43:526-35.
36. Sandmeier B, Jäger VK, Nagy G, et al. Autopsy versus clinical findings in patients with systemic sclerosis in a case series from patients of the EUSTAR database. Clin Exp Rheumatol 2015;33(4 Suppl 91):S75-9.
37. Willems LM, Kwakkenbos L, Leite CC, et al. Frequency and impact of disease symptoms experienced by patients with systemic sclerosis from five European countries. Clin Exp Rheumatol 2014;32 (Suppl 86):88-93.
38. Vanthuyne M, Smith V, De Langhte E, et al. The Belgian Systemic Sclerosis Cohort: correlations between disease severity scores, cutaneous subsets, and autoantibody profile. J Rheumatol 2012;39:2127-33.
39. Avouac J, Walker UA, Hachulla E, et al. Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis 2016;75:103-9.